Pfizer, GlycoMimetics hit a snag before Phase III; Aveo bails on its HQ;

@FierceBiotech: Biosimilars outfit Coherus pitches an $86M IPO, targeting Enbrel and Humira. More | Follow @FierceBiotech

@JohnCFierce: FierceBiotech's 2014 Fierce 15 - Still trending, all week long. Ain't it cool? Report | Follow @JohnCFierce

@DamianFierce: Tomorrow is FDA decision date No. 4 for $ALIM and $PSDV's Iluvien, if you're into that sort of thing. Both trading up at the moment. | Follow @DamianFierce

@EmilyMFierce: How is it that only one person has been cured of #HIV? A new monkey study reveals clues. Story | Follow @EmilyMFierce

> Pfizer ($PFE) and GlycoMimetics ($GLYC) are delaying the start of their planned Phase III trial on rivipansel over a manufacturing issue Pfizer is "working diligently to remedy," according to the latter company. News

> The flagging Aveo Oncology ($AVEO) has terminated the least on its headquarters in an effort to cut costs, saving $110 million in the process. More

> Valeant Pharmaceuticals' ($VRX) Bausch + Lomb is touting positive Phase III results for loteprednol etabonate, an ocular gel for pain and inflammation following cataract surgery, planning to file for FDA approval in the second half of 2015. Item

Medical Device News

@FierceMedDev: ICYMI yesterday: HealthKit pulled from iPhone 6 after update crashes customers' phones. Article | Follow @FierceMedDev

@MichaelGFierce: Purdue team recreates tumor microenvironment to study cancer nanomed delivery. FierceDrugDelivery story | Follow @MichaelGFierce

@VarunSaxena2: Titan Pharma trial of implant for addicts on track. Story | Follow @VarunSaxena2

@EmilyWFierce: FDA OKs "tumor paint" made from scorpion venom for Phase I clinical trial. Article | Follow @EmilyWFierce

> DOD awards $67M in contracts to Zoll, Philips. Item

> Researchers develop noninvasive device to monitor brain blood flow. Story

> Former AdvaMed board chairman, eye care company CEO accused of insider trading. Article

Pharma News

@FiercePharma: Judge tosses RICO claims over AbbVie's Humira, AndroGel copay cards: | Follow @FiercePharma

@EricPFierce: ICYMI: Mylan proposes plan to avoid nitroglycerin shortage in Canada. Story | Follow @EricPFierce

> Novo Nordisk blueprints its obesity R&D push in Seattle. Item

> Valeant adds activist shareholder Ubben to board as Allergan takeover bid heats up. Article

> Sovaldi's nosebleed price reflects a trend, not an exception to the rule. Story

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.